🔗 Visit the ClinicalTrials.gov page for NCT02322814
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. | Oncogene | 2015 | 0.90 |
| 2 | A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. | Breast Cancer (Auckl) | 2016 | 0.79 |